Sponsor: SWOG
Sponsor Study ID: S2308
Study Title: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for low Tumor Burden Follicular Lymphoma
CTO #: 104120
NCT Number: NCT06337318
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Hodgkin's Lymphoma
Study Objectives: To compare the 3-year milestone progression free survival (PFS) probabilities in participants with previously untreated, low tumor burden follicular lymphoma randomized to the rituximab arm versus the mosunetuzumab arm. b. To compare progression free survival (PFS) in participants with previously untreated, low tumor burden follicular lymphoma randomized to the rituximab arm versus the mosunetuzumab arm.